EIKCS 2021: Biomarkers for kidney cancer

Dr Thomas Powles from St Barts Hospital, London spoke about the work looking for tissue-based biomarkers for renal cell carcinoma (RCC) for potential use in the clinic at the European International Kidney Cancer Symposium (EIKC) 2021 Virtual Meeting. To date, the only biomarker that is used is one to predict survival (prognosis) based on the […]

read more

EIKCS 2021: Combination therapies for metastatic kidney cancer: Which Approach?

The use of combination therapies for the first-line treatment of metastatic renal cell carcinoma (RCC) has increased significantly over the past 3 years. However, there are now a number of potential first-line treatments, and choosing the most suitable treatment for each individual patient can be difficult. In a presentation at the European International Kidney Cancer […]

read more

Potential biomarker to predict risk of recurrence after nephrectomy for locally advanced kidney cancer

Currently, the search for a reliable biomarker to identify those patients who are at risk of the cancer coming back after nephrectomy for renal cell carcinoma (RCC) has not been successful. A recent study looked at a protein called kidney injury molecule-1 (KIM-1) in patients with RCC and whether this protein could be used to […]

read more

IKCS 2020: Treatment selection in kidney cancer

During this interview, Dr Rana McKay from the University of California in San Diego gives a succinct overview of the 19th Annual Meeting of the International Kidney Cancer Symposium (IKCS 2020), including highlights from the meeting. She also discussed the effects of delaying surgery for patients with low stage (T1 and T2) renal cell carcinoma […]

read more

Individualising first line treatment for advanced kidney cancer

In recent years, a number of new, effective treatments have become available for advanced kidney cancer. However, with more drugs available it has become more difficult to decide which drugs to choose for particular patients, and in which order to use them. In addition, the new treatments do not work for all patients and they […]

read more

Liquid biopsies in kidney cancer

In this review, the key substances found in the blood, such as circulating free (cf)DNA, cfRNA, proteins, and exosomes (sacs containing proteins, DNA and/or RNA), which may act as biomarkers for monitoring the progression of clear cell renal cell carcinoma (ccRCC) are discussed. Limitations of these techniques and promising technologies that could help with the […]

read more

Nephritis as a potential predictor of response to immune checkpoint inhibitors in kidney cancer

This study, to be published in Journal for Immunotherapy of Cancer, looks at the immune-related adverse event, acute interstitial nephritis (inflammation of the kidney tissues), as a biomarker for response to immune checkpoint inhibitors. Using a database, the researchers identified 177 patients with metastatic renal cell carcinoma (RCC) who received at least one dose of […]

read more

γ-Glutamyltransferase as a biomarker in patients on nivolumab for metastatic kidney cacner

A protein called γ-glutamyltransferase can predict survival in patients with local and metastatic renal cell carcinoma (RCC); however, in patients treated with immune checkpoint inhibitors, such as nivolumab, this predictive role is unknown. A study to be published in the International Journal of Clinical Oncology aimed to investigate the role of γ-glutamyltransferase as a predictive […]

read more

Treatment selection for metastatic kidney cancer based on gene expression

The discovery of a reliable biomarker for metastatic renal cell carcinoma (RCC) to predict response to treatment has been difficult to identify. This study was presented at the European Society of Medical Oncology (ESMO) Virtual Congress in September this year. The interview started by describing the currently used scoring systems used to categorise patients into […]

read more

Biomarkers for avelumab plus axitinib in advanced kidney cancer

The discovery of a reliable biomarker for how patients with advanced renal cell carcinoma (RCC) will respond to treatment has been very difficult to find. In this study, baseline samples from RCC tumours from patients in the phase III JAVELIN Renal 101 trial were analysed. The study showed that neither the presences of a biomarker […]

read more
Showing 1 to 10 of 83 results
  TOP